Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Acrivon TherapeuticsACRV +3.90%34 Net Cash per Share is $1.81 as of Jun. 2026. GuruFocus rates ACRV with a GF Score™ of 34/100. The stock has 3 warning signs investors should review. Among 763 Biotechnology companies, Acrivon Therapeutics ranks better than 90.69% on this metric.
Acrivon Therapeutics (NAS:ACRV) Net Cash per Share Explanation
Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.
Acrivon Therapeutics Net Cash per Share Related Terms
Acrivon Therapeutics Net Cash per Share Historical Data
* Premium members only.
The historical data trend for Acrivon Therapeutics's Net Cash per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ACRV vs DWTX, RLYB, ALDX: Net Cash per Share Comparison
For the Biotechnology subindustry, Acrivon Therapeutics's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Acrivon Therapeutics Price-to-Net-Cash vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Acrivon Therapeutics's Price-to-Net-Cash distribution charts can be found below:
* The bar in red indicates where Acrivon Therapeutics's Price-to-Net-Cash falls into.
Acrivon Therapeutics Net Cash per Share Calculation
In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.
Acrivon Therapeutics's Net Cash per Share for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Acrivon Therapeutics (ACRV) has a Net Cash per Share of $1.81 as of Jun. 2026. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Acrivon Therapeutics and its competitors. According to the industry distribution chart, Acrivon Therapeutics ranks #71 out of 763 companies in the Biotechnology industry, placing it in the top 9.3%.
Is Acrivon Therapeutics' Net Cash per Share too high?
Acrivon Therapeutics' current Net Cash per Share is $1.81. The Biotechnology industry median Net Cash per Share is 5.24. Acrivon Therapeutics' value of $1.81 is 65.5% below this industry median. Based on the distribution chart, Acrivon Therapeutics ranks #71 out of 763 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Acrivon Therapeutics has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Acrivon Therapeutics' Net Cash per Share compare to DWTX and RLYB?
According to the Biotechnology industry distribution chart, Acrivon Therapeutics ranks #71 out of 763 companies for Net Cash per Share. This places Acrivon Therapeutics in the top 9% of its industry — outperforming the majority of peers. The industry median Net Cash per Share is 5.24. Acrivon Therapeutics' value of $1.81 is 65.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Cash per Share for a Biotechnology company?
The median Net Cash per Share among Biotechnology companies is 5.24, based on 763 companies in the industry. Companies in the top quartile (top 25%) have a Net Cash per Share significantly above this median, while those in the bottom quartile fall well below. However, Net Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Acrivon Therapeutics's current Net Cash per Share of $1.81 is 65.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Cash per Share mean?
A high Net Cash per Share can signal that a stock is expensive relative to its fundamentals. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Acrivon Therapeutics and its competitors. For the Biotechnology industry, the median Net Cash per Share is 5.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Acrivon Therapeutics's current Net Cash per Share is $1.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acrivon Therapeutics stock overvalued right now?
Acrivon Therapeutics (ACRV) has a current Net Cash per Share of $1.81. The current Net Cash per Share is $1.81 and 65.5% below the Biotechnology industry median of 5.24. Acrivon Therapeutics' overall GF Score™ is 34/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Cash per Share calculated?
Net Cash per Share is calculated from a company's financial statements. For Acrivon Therapeutics (ACRV), the current Net Cash per Share is $1.81 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.
34GF Score
Get the complete analysis for ACRV
Net Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ACRV has been successfully added to your 
